SILO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SI

Volume

10.08K

Next Earnings

November 12th

Loading chart

SI

SILOSilo Pharma, Inc. Common Stock

SILO

Pay with—

Available Balance0.00

SI

Mkt Cap

$2.5M

Volume

10.08K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI PlatformSilo Pharma's subsidiary QwikAgents has partnered with Caylent, an AWS Premier Tier Services Partner, to build a new AWS-native platform. The collaboration aims to enhance scalability, performance, and security for enterprise deployment, with expected funding support from AWS and Caylent to accelerate commercialization and product innovation.GlobeNewswire Inc. · Aug 6, 2026

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug ProgramSilo Pharma announced progress on two strategic fronts: its QwikAgents AI subsidiary is preparing for commercial launch within 60-90 days to generate initial revenue in the enterprise AI market, while its lead PTSD therapeutic candidate SPC-15 advances through regulatory milestones including completion of a drug-device robustness study and preparation for an FDA Type C meeting. The company recently raised capital through a private placement to support these initiatives.GlobeNewswire Inc. · Jul 21, 2026

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent PlatformSilo Pharma announced that its subsidiary QwikAgents has been accepted into Advanced Micro Devices' AMD AI Developer Program. The acceptance provides access to AMD Developer Cloud credits, AI development tools, and technical resources to support QwikAgents' next-generation AI agent platform designed for individuals, developers, small businesses, and enterprises.GlobeNewswire Inc. · Jul 14, 2026

Stock Market Today: Dow, S&P 500 Futures Drop Ahead Of Trump's 'Power Plant Day' Deadline— UnitedHealth, Silo Pharma, Phillips 66 In Focus (UPDATED)U.S. stock futures rose on Tuesday as investors awaited Trump's deadline regarding Iran's Strait of Hormuz. UnitedHealth Group surged 6.86% following favorable Medicare Advantage payment rates, while Silo Pharma jumped 45.31% on a patent approval for PTSD treatment. Phillips 66 declined 0.75% due to reported losses from rising oil prices amid geopolitical tensions. The S&P 500 and Nasdaq Composite posted modest gains, with analysts maintaining optimistic outlooks for 2026 despite ongoing market volatility.Benzinga · Apr 7, 2026

Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury ManagementSilo Pharma has initiated a strategic partnership with Fireblocks to develop an institutional-grade infrastructure for managing digital assets, leveraging Fireblocks' secure digital asset custody and transfer capabilities.GlobeNewswire Inc. · Sep 29, 2025

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and FibromyalgiaSilo Pharma announced positive results from an initial study of its SP-26 ketamine extended-release implant for chronic pain and fibromyalgia, with no serious side effects observed. The company expects final safety and absorption data in March 2025.GlobeNewswire Inc. · Feb 11, 2025

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic PainSilo Pharma is making progress in developing its lead assets SPC-15 and SP-26 for the treatment of PTSD, stress-induced anxiety, and chronic pain. The company is preparing to submit an IND for SPC-15 in 2025 and is advancing animal studies for SP-26 ketamine implants.GlobeNewswire Inc. · Jan 2, 2025

Silo Pharma secures $2.1 million in direct offering - Investing.comSilo Pharma, a biopharmaceutical company, has announced a $2.1 million direct offering to fund its work on novel therapies for psychiatric disorders, chronic pain, and CNS diseases. The company has made advancements in its Alzheimer's and PTSD drug development programs.Investing.com · Jul 19, 2024

Gold Down 2%; SLB Posts Upbeat Earnings - BenzingaU.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 300 points. Schlumberger reported better-than-expected second-quarter results, with revenue and adjusted EPS beating consensus estimates.Benzinga · Jul 19, 2024

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswireSilo Pharma, a biopharmaceutical company, announced a $2.1 million registered direct offering of common stock and warrants. The company plans to use the proceeds for working capital and general corporate purposes.GlobeNewswire Inc. · Jul 19, 2024

to start trading

SI

SILOSilo Pharma, Inc. Common Stock

SILO

Pay with—

Available Balance0.00

Your PositionYou don't own any SILO yet.

Related Tickers

Earnings